Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in Patients With Type 2 Diabetes Mellitus
NCT05516966Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- May 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS9531 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Incidence of Adverse Events (Safety and Tolerability) at Day 62. Started Oct 2022; status: completed.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05516966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516966.